http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013119595-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 |
| filingDate | 2011-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013119595-A |
| titleOfInvention | LOW-DOSE PHARMACEUTICAL COMPOSITION |
| abstract | 1. A pharmaceutical composition comprising zanamivir and one or more pharmaceutically acceptable excipients, in which the total daily dose of zanamivir is less than 10 mg. The pharmaceutical composition according to claim 1 for administration at least once a day. The pharmaceutical composition according to claim 1, wherein the composition delivers from 3 mg to 8 mg of zanamivir per administration dose. The pharmaceutical composition according to claim 1, designed for use by a dry powder inhaler (DPI), a metered dose inhaler (MDI), a nebulizer, a nasal spray, nasal drops or powder for injection. The pharmaceutical composition according to claim 4, designed for use as a dry powder form for inhalation. The pharmaceutical composition according to claim 5, further comprising at least one finely divided pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulations. The combination composition of claim 6, wherein said carrier comprises a saccharide and / or sugar alcohol. The pharmaceutical composition according to any one of claims 5, 6 or 7, wherein the pharmaceutical composition is encapsulated or blister-packed or enclosed inside a reservoir in a single or multi-dose dry powder inhalation device. The pharmaceutical composition according to any one of claims 5, 6 or 7, wherein the pharmaceutical composition is administered via Revolizer ™. 10. The pharmaceutical composition according to any one of claims 1 to 7, additionally containing one or more active substance (s) selected from amantadine, rimantadine, acyclovir, azidothymidine, vidarabine, ribavirin, dapsone, chloramphenicol, not |
| priorityDate | 2010-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.